JAZZ

Jazz Pharmaceuticals Plc - 10-Q Summary (Q2 2010)

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2010. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on neurology, psychiatry, and rheumatology. Its primary marketed products are Xyrem (sodium oxybate) for narcolepsy and Luvox CR (fluvoxamine maleate) for OCD and social anxiety disorder. The company is awaiting FDA approval for JZP-6 (sodium oxybate) for the treatment of fibromyalgia, with an FDA Advisory Committee meeting scheduled for August 20, 2010.

Key Financial Metrics

Note: Net loss for the six-month period was significantly impacted by a $12.287 million loss on the extinguishment of debt.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 27.5% to $75.7 million from $59.4 million in the prior year period. Product sales rose 54% to $73.8 million, driven by price increases and volume growth in Xyrem (up 56%) and Luvox CR (up 47%).
• Contract Revenue Decline: Contract revenues dropped significantly to $0.6 million from $10.6 million in the prior year, as the $10 million milestone payment recognized in Q2 2009 was a non-recurring item.
• Debt Restructuring: The company repaid $119.5 million in senior secured notes (carrying a 15% interest rate) and entered a new credit agreement in June 2010. This reduced total debt to approximately $57.4 million and lowered the interest rate to a variable rate of 5.75%.
• Operating Expenses: Research and development expenses decreased 37% to $14.2 million due to the completion of Phase III trials for JZP-6. Selling, general, and administrative expenses increased 22% to $33.9 million due to pre-launch planning for JZP-6.

Guidance, Outlook, and Risks

• Outlook: Management expects Xyrem sales to be higher in 2010 due to price increases and continued single-digit volume growth. Luvox CR sales are also expected to increase. The company anticipates lower R&D spending in 2010 compared to 2009.
• Liquidity: The company raised $57.1 million in a public stock offering in May 2010. Management believes existing cash, operating cash flow, and the new revolving credit facility are sufficient to fund operations for the foreseeable future.
• Supply Chain Risk: The sole supplier of sodium oxybate (Lonza) is closing its plant. A new supplier (Siegfried) has been contracted, but both require DEA quota approvals which are pending. Failure to secure quotas could disrupt supply.
• Regulatory Risks: The company received an FDA warning letter in July 2010 regarding Luvox CR promotional materials. Additionally, generic competitors (Actavis and Anchen) have filed ANDAs for Luvox CR, leading to ongoing patent litigation.
• Healthcare Reform: The Patient Protection and Affordable Care Act is expected to increase rebate costs, potentially reducing net product sales by less than $1.0 million for the remainder of 2010.

Investor Verification Checklist

• DEA Quota Status: Verify if the new supplier (Siegfried) and current supplier (Lonza) have received sufficient DEA quotas to prevent supply shortages of Xyrem and JZP-6.
• JZP-6 Approval Probability: Monitor the outcome of the FDA Advisory Committee meeting scheduled for August 20, 2010, as approval is critical for future growth.
• Luvox CR Litigation: Track the status of patent infringement lawsuits against Actavis and Anchen, as generic entry could materially impact Luvox CR revenues.
• FDA Warning Letter Response: Confirm the resolution of the July 2010 FDA warning letter regarding Luvox CR marketing to ensure no further regulatory restrictions are imposed.
• Debt Covenants: Review compliance with the new credit agreement's financial covenants, specifically the minimum monthly liquidity requirement of $10 million (rising to $20 million).